🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Steven Cohen’s MLYS Holdings & Trades

First Buy
Q1 2023
Duration Held
8 Quarters
Largest Add
Q3 2025
+1.8 M Shares
Current Position
1.21 M Shares
$43.81 M Value

Steven Cohen's MLYS Position Overview

Steven Cohen (via Point72 Asset Management, L.P.) currently holds 1.21 M shares of Mineralys Therapeutics, Inc. (MLYS) worth $43.81 M, representing 0.05% of the portfolio. First purchased in 2023-Q1, this short-term holding has been held for 8 quarters.

Based on 13F filings, Steven Cohen has maintained this position in MLYS for several quarters, showing initial confidence in the investment. Largest addition occurred in Q3 2025, adding 1.8 M shares. Largest reduction occurred in Q4 2025, reducing 592,408 shares.

Analysis based on 13F filings available since 2013 Q2

Steven Cohen's Mineralys Therapeutics (MLYS) Holding Value Over Time

Track share changes against reported price movement

Quarterly Mineralys Therapeutics (MLYS) Trades by Steven Cohen

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 -592,408 Reduce 32.92% 1.21 M $36.29
Q3 2025 +1.8 M New Buy 1.8 M $37.92
Q2 2024 -47,800 Sold Out 0 $0.00
Q1 2024 -82,100 Reduce 63.20% 47,800 $12.91
Q4 2023 -33,285 Reduce 20.40% 129,900 $8.60
Q3 2023 +124,185 Add 318.42% 163,185 $9.51
Q2 2023 +34,000 Add 680.00% 39,000 $17.05
Q1 2023 +5,000 New Buy 5,000 $15.66

Steven Cohen's Mineralys Therapeutics Investment FAQs

Steven Cohen first purchased Mineralys Therapeutics, Inc. (MLYS) in Q1 2023, acquiring 5,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Steven Cohen has held Mineralys Therapeutics, Inc. (MLYS) for 8 quarters since Q1 2023.

Steven Cohen's largest addition to Mineralys Therapeutics, Inc. (MLYS) was in Q3 2025, adding 1,799,628 shares worth $68.24 M.

According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 1,207,220 shares of Mineralys Therapeutics, Inc. (MLYS), valued at approximately $43.81 M.

As of the Q4 2025 filing, Mineralys Therapeutics, Inc. (MLYS) represents approximately 0.05% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.

Steven Cohen's peak holding in Mineralys Therapeutics, Inc. (MLYS) was 1,799,628 shares, as reported at the end of Q3 2025.